Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo

Attila Cziraki, James Parkerson, Lyle E Fisher, John D. Catravas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The purpose of the present study was to contrast a commonly used ACE inhibitor (enalaprilat) with a novel ACE inhibitor (trandolaprilat) in their ability to inhibit 1) pulmonary capillary endothelial-bound ACE activity in vivo, 2) arterial pressure responses to i.v. angiotensin I and bradykinin, and 3) selected tissue ACE activity ex vivo, in rabbits. Pulmonary capillary endothelium-bound ACE activity in vivo was estimated via the single pass transpulmonary hydrolysis of the substrate 3H-Benzoyl-Phenylalanyl-Alanyl-Proline (BPAP), Doses of acutely administered trandolaprilat (8 μg/kg) or enalaprilat (10 μg/kg) were equieffective in reducing the presser response to angiotensin I. At these doses, trandolaprilat produced a greater inhibition of pulmonary capillary endothelial-bound ACE activity (66.5 ± 4.7% reduction of baseline BPAP metabolism vs. 52.7 ± 4.2% by enalaprilat, P < 0.05). Chronically administered trandolaprilat (8 μkg/day for 8 days) was more effective than enalaprilat (either 8 μg/kg/day or 10 μg/kg/day for 8 days) in reducing the angiotensin-1 induced increase in mean arterial pressure (increases of 9.7 ± 1.4 mmHg vs. 20.3 ± 2.3 mmHg and 19.1 ± 5.7 mmHg respectively; P < 0.01), as well as in reducing BPAP metabolism. In agreement with in vivo data, trandolaprilat was 5.5-, 3.6-, and 2.5-times more effective than enalaprilat in reducing ACE activities in the aorta, left ventricle, and lung, respectively. We conclude that trandolaprilat is a more potent, longer acting, and more tissue-selective ACE inhibitor than enalaprilat, and that the method outlined here can be used to aid in the development of tissue-specific ACE inhibitors.

Original languageEnglish (US)
Pages (from-to)22-30
Number of pages9
JournalDrug Development Research
Volume41
Issue number1
DOIs
StatePublished - May 1 1997

Fingerprint

Enalaprilat
Enzyme inhibition
Enzyme activity
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Lung
Proline
Angiotensin I
Tissue
Metabolism
Arterial Pressure
Vascular Endothelium
Angiotensins
Bradykinin
Heart Ventricles
Aorta
trandolaprilat
Hydrolysis
Rabbits
Substrates

Keywords

  • ACE inhibitors
  • Angiotensin converting enzyme
  • Enalaprilat
  • Hypertension
  • Pulmonary capillary endothelium
  • Tissue ACE activity
  • Trandolaprilat

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo. / Cziraki, Attila; Parkerson, James; Fisher, Lyle E; Catravas, John D.

In: Drug Development Research, Vol. 41, No. 1, 01.05.1997, p. 22-30.

Research output: Contribution to journalArticle

Cziraki, Attila ; Parkerson, James ; Fisher, Lyle E ; Catravas, John D. / Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo. In: Drug Development Research. 1997 ; Vol. 41, No. 1. pp. 22-30.
@article{e51c47401ab9450eba38ebae383048f4,
title = "Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo",
abstract = "The purpose of the present study was to contrast a commonly used ACE inhibitor (enalaprilat) with a novel ACE inhibitor (trandolaprilat) in their ability to inhibit 1) pulmonary capillary endothelial-bound ACE activity in vivo, 2) arterial pressure responses to i.v. angiotensin I and bradykinin, and 3) selected tissue ACE activity ex vivo, in rabbits. Pulmonary capillary endothelium-bound ACE activity in vivo was estimated via the single pass transpulmonary hydrolysis of the substrate 3H-Benzoyl-Phenylalanyl-Alanyl-Proline (BPAP), Doses of acutely administered trandolaprilat (8 μg/kg) or enalaprilat (10 μg/kg) were equieffective in reducing the presser response to angiotensin I. At these doses, trandolaprilat produced a greater inhibition of pulmonary capillary endothelial-bound ACE activity (66.5 ± 4.7{\%} reduction of baseline BPAP metabolism vs. 52.7 ± 4.2{\%} by enalaprilat, P < 0.05). Chronically administered trandolaprilat (8 μkg/day for 8 days) was more effective than enalaprilat (either 8 μg/kg/day or 10 μg/kg/day for 8 days) in reducing the angiotensin-1 induced increase in mean arterial pressure (increases of 9.7 ± 1.4 mmHg vs. 20.3 ± 2.3 mmHg and 19.1 ± 5.7 mmHg respectively; P < 0.01), as well as in reducing BPAP metabolism. In agreement with in vivo data, trandolaprilat was 5.5-, 3.6-, and 2.5-times more effective than enalaprilat in reducing ACE activities in the aorta, left ventricle, and lung, respectively. We conclude that trandolaprilat is a more potent, longer acting, and more tissue-selective ACE inhibitor than enalaprilat, and that the method outlined here can be used to aid in the development of tissue-specific ACE inhibitors.",
keywords = "ACE inhibitors, Angiotensin converting enzyme, Enalaprilat, Hypertension, Pulmonary capillary endothelium, Tissue ACE activity, Trandolaprilat",
author = "Attila Cziraki and James Parkerson and Fisher, {Lyle E} and Catravas, {John D.}",
year = "1997",
month = "5",
day = "1",
doi = "10.1002/(SICI)1098-2299(199705)41:1<22::AID-DDR3>3.0.CO;2-U",
language = "English (US)",
volume = "41",
pages = "22--30",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Inhibition of pulmonary endothelial angiotensin converting enzyme activity by trandolaprilat in vivo

AU - Cziraki, Attila

AU - Parkerson, James

AU - Fisher, Lyle E

AU - Catravas, John D.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - The purpose of the present study was to contrast a commonly used ACE inhibitor (enalaprilat) with a novel ACE inhibitor (trandolaprilat) in their ability to inhibit 1) pulmonary capillary endothelial-bound ACE activity in vivo, 2) arterial pressure responses to i.v. angiotensin I and bradykinin, and 3) selected tissue ACE activity ex vivo, in rabbits. Pulmonary capillary endothelium-bound ACE activity in vivo was estimated via the single pass transpulmonary hydrolysis of the substrate 3H-Benzoyl-Phenylalanyl-Alanyl-Proline (BPAP), Doses of acutely administered trandolaprilat (8 μg/kg) or enalaprilat (10 μg/kg) were equieffective in reducing the presser response to angiotensin I. At these doses, trandolaprilat produced a greater inhibition of pulmonary capillary endothelial-bound ACE activity (66.5 ± 4.7% reduction of baseline BPAP metabolism vs. 52.7 ± 4.2% by enalaprilat, P < 0.05). Chronically administered trandolaprilat (8 μkg/day for 8 days) was more effective than enalaprilat (either 8 μg/kg/day or 10 μg/kg/day for 8 days) in reducing the angiotensin-1 induced increase in mean arterial pressure (increases of 9.7 ± 1.4 mmHg vs. 20.3 ± 2.3 mmHg and 19.1 ± 5.7 mmHg respectively; P < 0.01), as well as in reducing BPAP metabolism. In agreement with in vivo data, trandolaprilat was 5.5-, 3.6-, and 2.5-times more effective than enalaprilat in reducing ACE activities in the aorta, left ventricle, and lung, respectively. We conclude that trandolaprilat is a more potent, longer acting, and more tissue-selective ACE inhibitor than enalaprilat, and that the method outlined here can be used to aid in the development of tissue-specific ACE inhibitors.

AB - The purpose of the present study was to contrast a commonly used ACE inhibitor (enalaprilat) with a novel ACE inhibitor (trandolaprilat) in their ability to inhibit 1) pulmonary capillary endothelial-bound ACE activity in vivo, 2) arterial pressure responses to i.v. angiotensin I and bradykinin, and 3) selected tissue ACE activity ex vivo, in rabbits. Pulmonary capillary endothelium-bound ACE activity in vivo was estimated via the single pass transpulmonary hydrolysis of the substrate 3H-Benzoyl-Phenylalanyl-Alanyl-Proline (BPAP), Doses of acutely administered trandolaprilat (8 μg/kg) or enalaprilat (10 μg/kg) were equieffective in reducing the presser response to angiotensin I. At these doses, trandolaprilat produced a greater inhibition of pulmonary capillary endothelial-bound ACE activity (66.5 ± 4.7% reduction of baseline BPAP metabolism vs. 52.7 ± 4.2% by enalaprilat, P < 0.05). Chronically administered trandolaprilat (8 μkg/day for 8 days) was more effective than enalaprilat (either 8 μg/kg/day or 10 μg/kg/day for 8 days) in reducing the angiotensin-1 induced increase in mean arterial pressure (increases of 9.7 ± 1.4 mmHg vs. 20.3 ± 2.3 mmHg and 19.1 ± 5.7 mmHg respectively; P < 0.01), as well as in reducing BPAP metabolism. In agreement with in vivo data, trandolaprilat was 5.5-, 3.6-, and 2.5-times more effective than enalaprilat in reducing ACE activities in the aorta, left ventricle, and lung, respectively. We conclude that trandolaprilat is a more potent, longer acting, and more tissue-selective ACE inhibitor than enalaprilat, and that the method outlined here can be used to aid in the development of tissue-specific ACE inhibitors.

KW - ACE inhibitors

KW - Angiotensin converting enzyme

KW - Enalaprilat

KW - Hypertension

KW - Pulmonary capillary endothelium

KW - Tissue ACE activity

KW - Trandolaprilat

UR - http://www.scopus.com/inward/record.url?scp=0030726756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030726756&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2299(199705)41:1<22::AID-DDR3>3.0.CO;2-U

DO - 10.1002/(SICI)1098-2299(199705)41:1<22::AID-DDR3>3.0.CO;2-U

M3 - Article

VL - 41

SP - 22

EP - 30

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 1

ER -